Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income.
Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy profile as the share prices have been battered, and the yields are high enough to make some investors wonder whether the market is flashing a warning.
But the deeper read is different as all three companies are still producing cash, all three are still paying their dividends, and in each case the payout remains tied to a business model that is more durable than the stock chart suggests.
Current yields work out to about 5.7% for EPD, 6.5% for Pfizer and 6.8% for UPS at today’s prices.
EPD: Pipeline business built for ugly markets
Enterprise Products Partners is not an oil producer, so it does not live and die with commodity prices.
It is a fee-based midstream operator that gets paid to transport, store and process hydrocarbons through a sprawling US network.
That model matters because it turns EPD into something closer to a toll road than a bet on crude prices.
The company says it has raised its distribution for 27 consecutive years, and its first-quarter 2026 results showed why income investors keep coming back.
Enterprise generated $2.7 billion of distributable cash flow in the quarter and said that cash supported another 2.8% increase in the distribution.
That is the key point for anyone tempted to sell after a slump. EPD’s payout is not being funded by hope or leverage; it is being funded by recurring cash flow.
The company retained $1.5 billion of DCF in the quarter after distributions, money it can use for growth projects, buybacks, or debt reduction.
Pfizer: Market has already priced in a very grim future
Pfizer is the most bruised name in the group. The stock is far below its pandemic-era peak, but the business is not standing still.
Pfizer’s 2025 annual review says revenue came in at $62.6 billion, and the company has continued to lean on cost cuts and its post-Seagen oncology portfolio as it tries to rebuild growth.
It also just declared another $0.43 quarterly dividend, its 350th consecutive quarterly payout.
The market’s problem with Pfizer is not that the story is broken; it is that expectations are extremely low.
The company reaffirmed its 2026 outlook for revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, while continuing to highlight cost savings and new-product momentum.
That leaves room for a re-rating if execution stabilizes.
In other words, investors selling now are not just taking a loss. They are also giving up a 6%-plus yield at a point when the stock is already priced for disappointment.
UPS: Dividend is living through a restructuring
UPS is the hardest of the three to own because the business has been shrinking in places that used to matter a lot.
But the company is clearly in a deliberate restructuring, not an uncontrolled decline.
Its latest quarter showed $21.2 billion in revenue, with management reiterating a 2026 revenue target of about $89.7 billion and an adjusted operating margin goal of 9.6%.
UPS has also said it is cutting Amazon volume sharply, while targeting about $3 billion in year-over-year cost savings in 2026 after roughly $600 million of savings in the first quarter alone.
That matters because the dividend story rests on cash generation.
UPS approved a quarterly dividend of $1.64 per share, and the company’s annual report shows 2025 revenue of $88.7 billion.
The yield is high because the share price is low, not because the payout has already cracked.
The post Why selling these 3 dividend stocks could be a mistake appeared first on Invezz
